Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Normal Healthy Subject Population Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

NCT07231991
View directory record Official record
Conditions
Healthy Participants
Interventions
vepdegestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Belimumab Administered Subcutaneously to Healthy Subjects

NCT01583530
View directory record Official record
Conditions
Healthy
Interventions
Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

NCT06268860
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
Drug · Combination Product
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cumulative Irritation Potential of 828 Ointment

NCT00767455
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HP828-101
Device
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

NCT05224609
View directory record Official record
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Tustin, California • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

NCT06438263
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

NCT00808769
View directory record Official record
Conditions
Normal Healthy Subject Population
Interventions
Zegerid®, Prilosec OTC®
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

NCT00169559
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GW590735, fenofibrate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 2, 2026, 10:17 PM EDT
Completed No phase listed Observational

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

NCT03327870
View directory record Official record
Conditions
Sjogren's Syndrome, Oral Health
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

NCT04668066
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-07242813, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Anaheim, California • Fountain Valley, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2005 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

NCT03799848
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425
View directory record Official record
Conditions
NASH
Interventions
EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

NCT01894360
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 200 mg/mL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed No phase listed Observational

Study of Taste Deficits

NCT00022997
View directory record Official record
Conditions
Taste Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973
View directory record Official record
Conditions
Severe Renal Impairment
Interventions
RANEXA
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

NCT03627754
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Glasdegib 100 mg single oral dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

NCT03443063
View directory record Official record
Conditions
Renal Impairment
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570
View directory record Official record
Conditions
Moderate Hepatic Impairment, Normal Hepatic Function
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT01429337
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Midostaurin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 2, 2026, 10:17 PM EDT